Prior to the present study, six of the nine potential molecular targets (EZH2, CDC6, PBK, KIF18A, HMMR and DLG7) were shown to be up-regulated in GBM [31–35], thus underscoring the relevance of our study. The gene discussed is EZH2; the disease is glioblastoma.